Capricor Therapeutics
Coverage of Capricor Therapeutics in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel rejected a Duchenne muscular dystrophy drug by a 9-to-3 vote due to insufficient effectiveness data, and the FTC sued Hims & Hers over alleged misleading health data practices and subscription billing issues.
- STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
Capricor Therapeutics accuses Nippon Shinyaku of failing to follow through on marketing plans for a Duchenne muscular dystrophy treatment. A pricing glitch in their distribution agreement would make the therapy economically impractical for patients covered by Medicare, Medicaid, and private insurers. The issue was disclosed in March 2025.
- STAT+: The biotech news you need to read today
Capricor Therapeutics is suing its partner Nippon Shinyaku over the launch of its Duchenne therapy, claiming they botched preparations and created an inaccessible pricing structure. The biotech company is fighting for its promising treatment, deramiocel. This lawsuit may impact the accessibility of the treatment for patients.